	US 12,319,693 B2
	Crystalline forms of CFTR modulators
Yi Shi, Natick, MA (US); Kevin J. Gagnon, Acton, MA (US); Jicong Li, Cambridge, MA (US); Jennifer Lu, San Diego, CA (US); Ales Medek, Winchester, MA (US); Muna Shrestha, Belmont, MA (US); Michael Waldo, Grafton, MA (US); Beili Zhang, San Diego, CA (US); Carl L Zwicker, Wakefield, MA (US); Corey Don Anderson, Brighton, MA (US); Jeremy J. Clemens, San Diego, CA (US); Thomas Cleveland, San Marcos, CA (US); Timothy Richard Coon, Carlsbard, CA (US); Bryan Frieman, La Jolla, CA (US); Peter Grootenhuis, Del Mar, CA (US); Sara Sabina Hadida Ruah, La Jolla, CA (US); Jason McCartney, Cardiff by the Sea, CA (US); Mark Thomas Miller, Rancho Santa Fe, CA (US); Prasuna Paraselli, San Diego, CA (US); Fabrice Pierre, La Jolla, CA (US); Sara E. Swift, San Diego, CA (US); and Jinglan Zhou, San Diego, CA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Oct. 24, 2023, as Appl. No. 18/493,667.
Application 18/493,667 is a continuation of application No. 16/992,441, filed on Aug. 13, 2020, granted, now 11,873,300.
Claims priority of provisional application 63/015,903, filed on Apr. 27, 2020.
Claims priority of provisional application 62/886,565, filed on Aug. 14, 2019.
Prior Publication US 2025/0051326 A1, Feb. 13, 2025
Int. Cl. C07D 401/14 (2006.01); A61K 31/4439 (2006.01); C07D 471/08 (2006.01)

CPC C07D 471/08 (2013.01) [C07B 2200/13 (2013.01)]

20 Claims

1. Compound I calcium salt hydrate Form A